coliand were not studied further

coliand were not studied further. We then tested each mutant protein for its ability to bind and bend a longer DNA site (nac) and a shorter site (cod) as described in Motesanib (AMG706) research37, which also appears with this journal issue. a NAC that could bind and repress transcription but not activate transcription. The I71A substitution resulted in a NAC polypeptide that remained monomeric. NAC tetramers can bind to both long and shorter binding sites (like other LTTRs). However, the absence of a coeffector to induce the conformational change needed for the switch from the former to the latter raised a question. Are there two conformations of NAC, analogous to the other LTTRs? The G217R substitution resulted in a NAC that could bind to the longer sites but had difficulty in binding to the shorter sites, and the I222R and A230R substitutions resulted in a NAC that could bind to the shorter sites but had difficulty in binding properly to the longer sites. Thus, Motesanib (AMG706) there appear to be two conformations of NAC that can freely interconvert in the absence of a coeffector. The LysR-type transcriptional regulator (LTTR) family Motesanib (AMG706) contains the highest number of regulatory proteins in the bacterial world, with more than 23,000 identified in the completed bacterial genome sequences as of March 2009 (43). They are assembled as tetramers, which are in fact dimers of dimers (27,39). Like many transcriptional regulators, they contain two well-defined domains, an N-terminal DNA-binding domain name and a C-terminal regulatory domain name responsible for dimer-dimer interactions and for binding a regulatory coeffector. This coeffector is usually a small molecule that, when bound, moves the DNA-binding domains of the two dimers closer together such that a shorter DNA-binding site is usually recognized in the presence of the coeffector than in its absence (29,42,45,47). Despite their abundance, few LTTRs have been Motesanib (AMG706) crystallized and even fewer structures are available. Total structures of CbnR, and more recently TsaR and ArgP, have been solved at high resolution (28,29,48), and a complete DntR structure has also been solved, although its DNA-binding domain name was less well resolved (42). The C-terminal domains of several other LTTRs have been crystallized and their structures solved, but only after the DNA-binding domain name was removed (6,7,44,46). Unfortunately, no full-length LTTR structure has been solved in both the coeffector-bound and coeffector-free conformations, leaving us to extrapolate the effects seen from the C-terminal domain name structures, where both forms have been solved in several cases (see references6,7, and42for examples). The nitrogen assimilation control protein, NAC, fromKlebsiella pneumoniaeis in Rabbit Polyclonal to DPYSL4 many ways a typical LTTR. It shows sequence similarity to the family (40), it is a dimer of dimers (38), it activates some genes and represses others (25,41), it has the common two domains (31,40), and it has proved recalcitrant to our attempts at crystallization. But in other ways, NAC is usually a special case among the LTTRs. At most of the sites where NAC activates transcription, it functions as a dimer (18,38). Other functionally dimeric LTTRs are known, e.g., MetR (23); however, even these LTTRs usually function in their tetrameric state to activate transcription. Truncated versions of NAC with as few as 86 amino acids (of the 305 total) are able to activate transcription at many, if not all, sites (31,38). The NAC regulon is usually unusually large, with scores of genes binding and responding to NAC-mediated activation or repression (11). NAC has no physiologically relevant coeffector (13,41). The decision to activate or repress gene expression is determined solely by whether NAC is made and not by a differential activity of the NAC once made (41). Although NAC tetramers can recognize both longer and shorter binding sites (like other LTTRs), it does so without the intervention of any coeffector or modification (37). This suggested that NAC tetramers can undergo a conformational change from a more compact to a more extended form in response to the DNA site presented to them, a conformational change that corresponds to the change induced by the binding of coeffectors in other LTTRs (37). Motesanib (AMG706) In addition, we have.